CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF
The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
1 . A means for inhibiting Bruton's tyrosine kinase (BTK).
2 . The means of claim 1 , wherein the means for inhibiting BTK is a BTK inhibitor compound.
3 . The means of claim 1 , wherein the means for inhibiting BTK is a crystalline BTK inhibitor compound.
4 . The means of claim 1 , wherein the means for inhibiting BTK is Compound 1:
5 . The means of claim 1 , wherein the means for inhibiting BTK is a crystalline form of Compound 1:
6 . A pharmaceutical composition comprising (a) a means for inhibiting BTK and (b) a pharmaceutically acceptable excipient.
7 . The pharmaceutical composition of claim 6 , wherein the means for inhibiting BTK is a BTK inhibitor compound.
8 . The pharmaceutical composition of claim 6 , wherein the means for inhibiting BTK is a crystalline BTK inhibitor compound.
9 . The pharmaceutical composition of claim 6 , wherein the means for inhibiting BTK is Compound 1:
10 . The pharmaceutical composition of claim 6 , wherein the means for inhibiting BTK is a crystalline form of Compound 1:
11 . A method for treating mantle cell lymphoma in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 1 .
12 . A method for treating mantle cell lymphoma in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 2 .
13 . A method for treating mantle cell lymphoma in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 3 .
14 . A method for treating mantle cell lymphoma in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 4 .
15 . A method for treating mantle cell lymphoma in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 5 .
16 . The method of claim 15 , wherein the subject has received at least one prior therapy.
17 . A method for treating Waldenstrom's macroglobulinemia in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 1 .
18 . A method for treating Waldenstrom's macroglobulinemia in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 2 .
19 . A method for treating Waldenstrom's macroglobulinemia in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 3 .
20 . A method for treating Waldenstrom's macroglobulinemia in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 4 .
21 . A method for treating Waldenstrom's macroglobulinemia in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 5 .
22 . A method for treating marginal zone lymphoma in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 1 .
23 . A method for treating marginal zone lymphoma in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 2 .
24 . A method for treating marginal zone lymphoma in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 3 .
25 . A method for treating marginal zone lymphoma in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 4 .
26 . A method for treating marginal zone lymphoma in a subject, comprising administering to the subject in need thereof a means for inhibiting BTK according to claim 5 .
27 . The method of claim 26 , wherein the subject has received at least one prior therapy.